11 European centres and represented patients on whom a DNA sample and clinical data was available. The study group was heterogeneous for age, stage of disease at transplant (32 patients in advanced stage disease), source of stem cells (50 patients received a PBSC graft), G VHD prophylaxis, and manipulation of graft (47 patients received a T cell depleted graft). Analysis for GVHD was by multivariable logistic regression, and for survival by Cox regression. Acute GVHD: occurrence of aGVHD associated with previously identified risk factors of gender mismatch (F to M)(OR 1.928 P = 0.082) use of PBSC (OR 0.378, P = 0.035), T cell depletion (OR 0.2, P = 0.002) and also with IL-6 genotype of the donor (GG at -174)(OR 1.994, P = 0.046). Chronic GVHD: protection effects were contributed by T cell depletion (OR 0.209, P=0.002) and a patient IL-10 GCC haplotype (OR 0.394, P=0.078). IL-6 GG donor genotype (OR 2.986, P=0.075) and patient genotype for IFN gamma (3,3 at intron 1 microsatellite)(OR 6.17, P=0.005) were associated with the occurrence of extensive cGVHD. Reduced survival was associated with patient age >40 years (OR 1.952, P = 0.011), advanced disease stage at time of transplant (OR 2.437, P = 0.003), genotype for TNFd (d3/d3)(OR 0.0479, P = 0.029) and IFN-gamma (3,3)(0.484, P = 0.037) both associated with increased likelihood of survival. Relapse was associated with increased patient age, advanced disease stage; previous aGVHD was protective for relapse. The identification of genetic risk factors in such a heterogeneous patient group suggests that genetic risk factors may represent robust and widely applicable risk factors suitable for use in patients entering a wide range of treatment protocols and modalities. The extension of these studies to examine these findings in individual treatment groups is therefore warranted.
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Factors influencing the incidence of GVHD after donor lymphocyte infusions in escalating doses for chronic myeloid leukemia F. Dazzi, S. Marktel, E. Nadal, R. Szydlo, E. Olavarria, A. Rahemtulla, E. Kanfer, J. Apperley, J. Goldman (London, UK) We have recently observed that administration regimen is the most important factor for acute GVHD after DLI. Incidence and severity of acute GVHD in pts receiving DLI with an escalating dose regimen (EDR) is much reduced as compared to pts receiving DLI with a bulk dose regimen, thus obscuring the role of further potential factors. Here we investigate factors for GVHD in pts undergoing EDR-DLI only. We analyzed 60 pts treated for chronic myeloid leukemia in relapse after conventional allogeneic SCT. 21 pts were in molecular, 22 in cytogenetic, 17 in hematologic relapse. Patients transplanted with a sibling (SIB) donor (n=26) received 10e7->5x10e7->10e8 donor CD3+ cells/Kg. Patients transplanted with a volunteer unrelated donor (VUD) (n=34) received 10e6->10e7->5x10e7->10e8 donor CD3+ cells/Kg. The median interval between doses was 22 weeks. 55 pts achieved molecular remission (91%). The overall incidence of acute (grade II-IV) and chronic GVHD was 21% and 13% (6% extensive), respectively. We observed a correlation between GVHD and response to DLI: all infusions resulting in acute GVHD grade II-IV (12/12) also produced molecular remission, whereas 43 of the 121 infusions (36%) not associated with GVHD (< grade II) resulted in molecular remission (p=0.00001). In accord, there was an inverse correlation between GVHD and relapse. None of the 12 pts who developed acute GVHD (grade II-IV) relapsed, whereas 4/43 (9%) of those with GVHD (< grade II) relapsed post-DLI. The donor type influenced the incidence but not the severity of acute GVHD (VUD 47% vs SIB 23%). Similarly, chronic GVHD was significantly higher in VUD as compared to SIB donors (17% vs 7%), but no difference in the severity of GVHD was recorded. We observed a correlation between the cell dose administered and acute GVHD grade II-IV. 7/60 pts (11%) developed acute GVHD after 10e6-10e7, as compared to 6/24 (25%) who developed acute GVHD after 5x10e7-10e8. The most important factor for acute GVHD was found to be the interval between transplant and initiation of DLI. 43% of the pts who started DLI before 1 year from transplant developed acute GVHD (II-IV) as compared to 15% who received the first dose at least 1 year after transplant. We conclude that donor type, cell dose, and interval between transplant and first DLI are important risk factors for GVHD post-DLI. This has important practical implications for the use of DLI in the context of reduced intensity conditioning SCT.
Oral Session: Supportive care and Regulatory issues O294 Total quality management in stem cell transplantationbeyond accreditation K. Aldous, G.M. Smith, R. Patmore, P. Hillmen, S.E. Kinsey, G. Cook (Leeds, UK) Total quality management (TQM), a common-sense strategy provides opportunity to examine and change the way we perform everyday tasks through a process of audit/continuous improvement. Accreditation through JACIE centres on 'reducing errors'. Yorkshire Blood and Bone Marrow Programme covering 5 stem cell transplant sites within a metropolitan a rea, is facilitating a 'culture change' to implement a quality improvement programme involving all staff. We developed a strategy reviewing the current service (annual transplant activity, service pressures, evolving role of Primary Care Trusts), pre-existing policies/procedures and Service Level Agreements. The strategy set the framework by identifying all 'customers' to whom the BMT programme provides or who provide the programme with a service. A continuous programme of patient/carer and staff audit is u ndertaken to analyse the current perception of the programme. A Mission Statement and Quality Policy stating the aims and objectives are posted in all clinical areas. Quality handbooks provide information on the implementation of tools used in TQM. A Clinical Policy Audit Group (CPAG) and Quality Management Group (QMG) fomulate clinical policies/guidelines, and Standard Operating Procedures (SOPs) break down the policies into everyday tasks respectively. SOPs are validated to assess their suitability and document control ensures that only current policies/SOPs are in use in each clinical area. Communication is facilitated in our model of TQM by named 'briefers' in each area responsible for receipt and timely briefing of all staff. Members of the QMG sponsor the setup of Quality Improvement Teams (QITs), to identify work processes aiming to improve communication, working methodologies, staff motivation, avoiding task duplication and improving cost efficiency. QITs feedback suggestions/recommendations to the sponsor and through the involvement of all staff in the centre, represent a process encouraging all to become involved in continuous improvement. Our model of TQM serves as a framework that forms the basis of a 'changed culture'. TQM will take a centre beyond accreditation by continuously improving the quality of service provided to patients.
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An open, randomized, phase II, single center, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-y2b in patients with myeloma maintained on a steady dose of interferon-y2b R. Powles, B. Sirohi, D. Lawrence, S. Sankpal, S. Kulkarni, D. Heming, H. Hollis, J. Treleaven, J. Mehta (Sutton, UK) Subject compliance with interferon-y2b (IFN) dosing during maintenance therapy for patients with myeloma is an important S43 factor for achieving intended clinical benefit. The significantly longer half-life of pegylated-IFN (PEG interferon (P-IFN);Schering-Plough) allows once-weekly dosing. Eligible patients on IFN maintenance for at least 6 wks were randomly (1:1) allocated to P-IFN x 3 months followed by IFN x 3 months, or to continue with IFN x 3 months followed by P-IFN x 3 months (crossover design). Patients were assessed for toxicity using the NCI-CTC throughout the study and were asked to complete an EORTC QLQ-C30 and EORTC-QLQ MY24 questionnaire to assess their quality of life (QoL) before the first randomised treatment and at 3 and 6 mo. Dose of P-IFN was equivalent to IFN. The main aim of the study was to compare the Global QoL score from QLQ-C30 on P-IFN and IFN. The study enrolled 60 patients (Median age, 51 y, 17F, 43M, 80% stage III). At enrolment, 33/60 (55%) patients were in CR, 14 (23%) in PR and 13 (22%) were minimal responders. 90% patients completed all 3 questionnaires and all patients completed at least 2 questionnaires. The data from the EORTC-QLQ-C30 has been analysed. Scores for each scale in the EORTC-QLQ-C30 questionnaire were calculated as suggested in the scoring manual. A higher score on functional scores i.e positive difference indicates P -IFN is better and a lower score on symptom scales i.e negative difference indicates P-IFN is better. P-IFN was associated with a statistically significantly better global QoL score (mean difference 8.33; 95%CI 4.2-14.98; P<0.001). Also there was a statistically significant improvement in the functional scales-physical (mean diff3.52;P=0.03),, emotional (mean diff5.5;P=0.04), social (mean diff8.49; P=0.001) with P-IFN. The fatigue (Mean diff -10.19;P<0.001), pain (mean diff -6.79; P=0.02) and appetite (mean diff -9.26; P=0.004) symptom scales were less in patients while they were on P-IFN. Though EORTC rates 10 or more as clinically important, our figures of below 10 may reflect the relative low level of symptoms relating to non-pegylated IFN. P-IFN did not have an impact on cognitive function, or the nausea, insomnia, constipation, diarrhea and financial worries symptom scales. These data suggest that patients on P-IFN have a statistically significantly better QoL and should become standard of care for maintenance therapy in patients with myeloma and dose escalation studies should be done to see an even better impact on survival.
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Defibrotide prevent efficiently hepatic veno-occlusive disease after allogeneic stem cell transplantation in adult Y. Chalandon, E. Roosnek, B. Mermillod, C. Helg, A. Newton, B. Chapuis (Geneva, CH) Veno-occlusive disease (VOD) of the liver occurs in 10-50% of patients after stem cell transplantation (SCT), with a mortality rate of up to 50%. Recently, promising results in the treatment of established VOD of the liver have been reported with infusion of defibrotide (Richardson et al. Blood 1998:92:737; Chopra et al. BJH 2000 :111:1122 . We conducted a single center trial of defibrotide (Prociclide® Crinos, Como, Italia) given as prophylactic regimen for hepatic VOD. Forty-eight successive adult patients were transplanted for hematological malignancies between September 1999 and May 2002. Median age was 38 y (range 18-60 y), M/F ratio = 25/23; diagnoses were AML=12, ALL=8, CML=15, MDS=7, NHL=4, MM=2. Thirty-three patients (69%) received stem cells from an HLA-identical sibling, 13 (27%) from an unrelated donor and 2 (4%) from a mismatched relative. Seventy-five percent received PBSC vs 25% BMT. The stem cells were partially (33(69%) patients) or totally T-depleted (6 (12%) patients) with CAMPATH-1H in vitro. Nine patients received unmanipulated SCT (19%). The majority of the patients (79%) received CY-TBI conditioning and 15% a reduced intensity regimen. GVHD prophylaxis was CSP-MTX+-MP in 32 patients (67%), CSP-MP+-ATG in 13 patients (27%), and other in 3 patients (6%). Defibrotide was given intravenously starting at day -7 up to day +20-28 post-transplantation (dose range 10-25 mg/kg/d) in addition to heparin.
Results: None of the 48 patients developed VOD (Baltimore criteria) and no side effects occurred. These results were significantly different (p = 0.0005) from 47 successive historical controls who were not given defibrotide (10/47 (21%) VOD, 3 of whom died of severe VOD). In addition, day 100 EFS was significantly higher in the group who received defibrotide (p=0.012) and there was a trend with better day 100 OS (p=0.07). This was correlated with a lower percentage of patients with a maximum total bilirubin >50 micmol/l (5/48 vs 18/47 p=0.002) as well as with a maximum aPTT > 50s (p=0.02) and a maximum PT> 1.5 INR (p=0.03). Conclusion: Our results, that should still be confirmed by a prospective randomized trial, suggest that defibrotide in addition to heparin is more efficient in preventing VOD than heparin alone.
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No clinically relevant toxicity shown in the preclinical safety assessment of the INTERCEPT blood system for platelets T. Sullivan, V. Ciaravino, T. McCullough (Concord, USA) The INTERCEPT Blood System for platelets uses amotosalen and UVA light in an ex vivo photochemical treatment (PCT) to inactivate viruses, bacteria, protozoa, and leukocytes in platelet concentrates while retaining therapeutic function. After UVA illumination and before transfusion, residual amotosalen and free amotosalen photoproduct levels are lowered by an amotosalen compound adsorption device (CAD). A comprehensive preclinical safety program, including carcinogenicity, was conducted based on the strategy normally applied to a new pharmaceutical. Studies were performed by intravenous infusion of amotosalen PCT formulations +/-CAD treatment and with unilluminated amotosalen, using doses that were multiples of potential clinical exposures. The completed studies were single-dose and multiple-dose (up to 13 weeks duration) toxicity, safety pharmacology (CNS, renal, and cardiovascular), reproductive toxicity, genotoxicity, p53 carcinogenicity, vein irritation, phototoxicity, and toxicokinetics (multiple dose pharmacokinetics). No specific target organ toxicity (clinical or histologic pathology) (>350-fold clinical exposure), reproductive toxicity (>350-fold clinical exposure), or carcinogenicity (~1,000-fold clinical exposure) was observed. Amotosalen and/or PCT formulations demonstrated CNS and electrocardiographic (ECG) effects at >25,000-fold the expected clinical exposures. Phototoxicity was observed at ~1,000-fold the expected clinical exposures. There was no positive genotoxicity with amotosalen PCT formulations. Amotosalen alone resulted in genotoxicity only in vitro at >17,000-fold circulating human plasma levels (without metabolic activation) and >45,000-fold (with metabolic activation). Amotosalen alone was not genotoxic in vivo at >40,000-fold human exposure. The levels at which effects were observed in phototoxicity studies are not considered relevant for the proposed use of the photochemically-treated platelets. The results of the toxicokinetic analyses from 3-month rat and dog studies with amotosalen PCT formulations +/-CAD treatment were compared with clinical data. These data indicate that formulations used in the key toxicology studies provided large multiples of the clinical exposure to amotosalen, whether the comparison was based on dose, Cmax, or AUC. Objective: To determine the safety, tolerability and potential for drug interactions (i.e. tacrolimus) of imatinib mesylate when used as adjuvant treatment (i.e. in the absence of hematological, cytogenetic or molecular evidence of disease) within the first one hundred days following Stem Cell Transplantation (SCT) in patients with Ph+ disease at high risk for relapse. Methods: A study (chart review) was conducted to evaluate the tolerability and toxicity of imatinib when used within the first 100 days following SCT. Results: SCT patients (n=15; M/F 12/3) ranging in age from 16-69 years (mean = 42 years) received imatinib as adjuvant therapy following SCT during the period 5/2001-6/2002. Disease states included Ph+ CML (n=8), Ph+ ALL (n=6) and Ph+ AML (n=1). Stem cell source included peripheral blood in 9/15 patients (60%), and bone marrow (n=6). 9/15 patients (60%) received their donor cells from an HLA matched sibling, 3/15 (20%) from a matched unrelated donor, 2/15 (12.4%) from a 1 -antigen mismatched related donor, and 1 patient received autologous SCT. Median day of imatinib initiation post transplant was day +34 after SCT (range 16-37). Initial imatinib doses ranged from 100 to 400 mg/day. The average daily dose administered was 100 mg per day. Doses exceeding 200 mg per day were associated with significant myelosuppression, which required both imatinib dose reduction and initiation of transfusion and growth factor support measures to achieve graft recovery. At all doses, imatinib was associated with reversible hematological toxicity, with Grade 3 and 4 neutropenia observed in 40% and 27% of patients respectively. Significant thrombocytopenia was also noted; with Grade 3 and 4 toxicity observed in 27% and 20% of all patients evaluated. Non-hematologic toxicities were uncommon; with per orbital edema/weight gain and transient elevation in total bilirubin (1.0 mg/dl to 2.3 mg/dl) noted in 1 patient each (6.7%). Administration of imatinib was found to predictably increase tacrolimus serum levels by 25-33% within 72 hours of medication initiation. Empiric tacrolimus dose reduction of 25% at the time of imatinib initiation prevented further serum concentration fluctuations. Conclusion: These preliminary observations suggest that imatinib can be safely administered within the first 100 days s/p SCT, although the tolerated doses are usually lower than in non-SCT patients.
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Combined dual-and single-platform FACS analyses to quantify leukocyte subsets for early prediction of engraftment following allogeneic SCT G. Fritsch, J. Pichler, S. Matthes, B. Keck, H. Gadner, C. Peters (Vienna, A) Engraftment following allogeneic SCT usually occurs between days + 5 and + 16 and is defined by a stable increase of WBC above 200/µl. WBC counts <200/µl cannot be reliably determined with conventional haematology analyzers, and FACS analyses of blood leukocytes usually require WBC counts of >500/µl. It is therefore difficult to analyze blood from leukopenic patients undergoing SCT after myeloablative conditioning. We combined and adapted 2 flow cytometric analysis procedures which allow, from a total of 2ml of blood, to quantify CD34+ cells, monocytes, granulocytes and T cells, at a level of 1-10 WBC/µl. We confirmed that the commercially available LeukoCountTM reagent allows linear detection of leukocytes down to 1 WBC/µl using 100µl of EDTA-anticoagulated blood (Pichler et al., Cytometry 2002) . The second analysis employs a dual-platform lyse-&-wash cell preparation procedure: Between 1 and 2 ml blood are subjected to RBC lysis using isotonic NH4Cl buffer. After washing, cells are resuspended in 50-100µl PBS/2%HSA, stained with a MAB cocktail containing CD45 FITC, CD15 FITC, CD38 RPE, CD3 PerCP and CD34 APC, and washed again. After acquisition, the leukocyte subtypes are evaluated using multi parameter data evaluation. Absolute cell numbers are calculated from the percentage values (2nd analysis) and the leukocyte counts (1st analysis). The described procedure is based on a several year experience with paediatric cancer patients. It has proven highly sensitive, and, at a level of <10 WBC/µl, reliably detects a possible rejection as well as haematopoietic engraftment. The early presence of T cells raises suspicion of rejection, which is confirmed by PCR-or FISH-based genotype analysis of FACSsorted cells. "FACS-engraftment" is defined by the appearance of monocytes, left-shifted granulocytes, and CD34+ cells in dynamic FACS analyses. It is clearly detectable at a median of 3.5 days before WBC increase above 200/µl, and 4 -10 days before granulocyte counts >500/µl. (Fritsch et al., Cytotherapy 1999; Peters et al., Leukemia 1999) Engraftment-related complications such as engraftment syndrome with fever and capillary leak, are frequently difficult to distinguish from acute septicaemia. The very early confirmation of haematologic engraftment is therefore helpful for therapeutic decisions concerning intensification of antibiotic/antifungal therapy or transfusion of granulocyte concentrates.
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Informatic drug management in a bone marrow transplant unit: towards an improvement of hospital drug management M. Krampera, F. Venturini, S. Carolei, H. Aqel, C. Visco, G. Scroccaro, G. Pizzolo, F. Benedetti (Verona, I) Drug treatment is frequently affected by complications arising from drug prescription or administration errors, which are the most common cause of adverse events in hospital patients. Computerised systems for drug management can be effective in reducing these errors, as long as they are easily exploitable even in emergency conditions. An informatic drug management project has started in May 2002 in our Bone Marrow Transplant Unit (BMTU) to manage the large number of prescribing procedures that are carried out simultaneously in patients undergoing BMT. From May to November 2002 54 patients were admitted and treated using the computerised system and 24011 administrations were carried out for a total of 228 drugs. No prescribing errors have been observed. 1) As far as patient care organisation is concerned, we observed: a. a significant decrease of both the time requested and the probability of errors in drug prescription; b. a precise operator identification, that allows to retrieve exactly all the steps in drug management; c. a real improvement in terms of medical updating by the constant control on drug side effects, contraindications and interactions in case of multiple prescriptions; d. a shorter time for drug supply and a better control of drug ordering and stocking. 2) As far as Pharmacy organisation is concerned, we observed: a. an improvement in drug supply, on the basis of the real drug utilisation; b. a useful "real-time" monitoring of critic patients' therapy c. a better calculation of drug use and therapy costs; d. the possibility to carry out studies of pharmaco-epidemiology. 3) As far as treatment monitoring by the Hospital Public System is concerned, we observed: a. an optimisation of the use of human (for a shorter time in drug prescription and in BMTU organisation) and economical (for the lower number of stocked drugs in the BMTU) resources; b. an improvement in the quality of the offered services by linking all the information concerning patients with the treatments performed. This possibility is a powerful tool to ensure continuity in patients' care all over their life. c. the possibility to have a detailed account of therapy costs for sigle patient. Taken together, these characteristics allow to consider the informatic system a reliable tool that can be useful to improve and speed up the procedures concerning drug management without jeopardising patient safety.
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The prognostic value of oxygenation index early after allogeneic hematopoetic stem cell transplantation: results of a prospective trial C. S. Schiemanck, G. Höffken, G. Ehninger, M. Bornhäuser, T. Illmer (Dresden, D) Background and objectives: Respiratory failure after allogeneic hematopoetic stem cell transplantation is a major cause of death. Acute lung injury can be defined in the course of lung disease by the continuous monitoring of oxigenation indices (Oxi-Index). Therefore, we monitored Oxi-Indices in a patient group who received allogeneic transplantation between November 2001 and October 2002. Methods: Oxi-Index was defined by the ratio of partial pressure of arterial oxygen (mmHg) to the fraction of inspired oxygen. With reference to the definition of the American-European Consensus Conference Committee for acute respiratory distress syndrome patients with Oxi-Indices below 300 were considered to have acute lung injury (ALI). In a prospective trial we monitored Oxi-Indices twice daily to assess respiratory function during the first 30 days after transplantation. 59 patients can now be evaluated for this time period. Results: During the observation period 15 out of 59 patients experienced ALI even before manifestation of clinical signs of respiratory distress. These patients presented as a high risk group for early transplant complications since 40% of them required admission to the ICU compared to 6.8% of the non-ALI patients (p<0.01). With respect to the time course of oxigenation after transplantation there was a decline of median oxigenation in the entire patient group around day 7 possibly reflecting early pulmonary toxicity but there were no differences between patient groups receiving myeloablative or non-myeloablative conditioning regimens. Frequency of orotracheal intubation was significantly increased in the ALI-patient group with 20% vs. 2,3% in the non-ALI-patient group (p<0,05). Conclusions: Monitoring Oxi-Indices proved to be diagnostically relevant to alert for progressive respiratory failure following allogeneic hematopoetic stem cell transplantation. Decline of Oxi-Indices seems to be an early indicator of respiratory distress, which identifies patients at high risk for early transplant related mortality. An interventional study to prove the impact of noninvasive ventilation in these patients is underway.
